Publications by authors named "Siegfried Seeber"

Claim this Profile
I
Improved survival in metastatic breast cancer: results from a 20-year study involving 1033 women treated at a single comprehensive cancer center.
Anja Welt, Simon Bogner, Marina Arendt, Josef Kossow, Antonia Huffziger, Siegfried Seeber

J Cancer Res Clin Oncol· June 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
1
10-year long-term survival (LTS) of induction chemotherapy with three cycles cisplatin/paclitaxel followed by concurrent chemoradiation cisplatin/etoposide/45 Gy (1.5 Gy bid) plus surgery in locally advanced non-small-cell lung cancer (NSCLC)-a multicenter phase-II trial (CISTAXOL).
Wilfried Ernst Erich Eberhardt, Thomas Christoph Gauler, Cecile Lepechoux, Georgios Stamatis, Stephan Bildat, Siegfried Seeber

Lung Cancer· October 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
High-level production of a humanized immunoRNase fusion protein from stably transfected myeloma cells.
Jürgen Krauss, Evelyn Exner, Athanasios Mavratzas, Siegfried Seeber, Michaela A E Arndt

Methods Mol Biol· April 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Long-term survival in patients with inoperable and metastasized cancer.
Siegfried Seeber

Onkologie· September 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Docetaxel and gemcitabine in the treatment of soft tissue sarcoma - a single-center experience.
Peter Ebeling, Lewin Eisele, Philipp Schuett, Sebastian Bauer, Jochen Schuette, Siegfried Seeber

Onkologie· February 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The clinical significance of soluble human leukocyte antigen class-I, ICTP, and RANKL molecules in multiple myeloma patients.
Philipp Schütt, Vera Rebmann, Dieter Brandhorst, Johannes Wiefelspütz, Peter Ebeling, Siegfried Seeber

Hum Immunol· February 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Long-term results of a phase-I/II study of sequential high-dose chemotherapy with autologous stem cell transplantation in the initial treatment of aggressive non-Hodgkin's lymphoma.
Anja Welt, Philipp Schütt, Cordula Derks, Peter Ebeling, Siemke Müller, Siegfried Seeber

Tumori· December 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A novel nonobese diabetic/severe combined immunodeficient xenograft model for chronic lymphocytic leukemia reflects important clinical characteristics of the disease.
Jan Dürig, Peter Ebeling, Florian Grabellus, Ursula R Sorg, Michael Möllmann, Siegfried Seeber

Cancer Res· September 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
Gene transfer of cytidine deaminase protects myelopoiesis from cytidine analogs in an in vivo murine transplant model.
Ina Rattmann, Veronika Kleff, Ursula R Sorg, Walter Bardenheuer, Annette Brueckner, Siegfried Seeber

Blood· November 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Immune parameters in multiple myeloma patients: influence of treatment and correlation with opportunistic infections.
Philipp Schütt, Dieter Brandhorst, Werner Stellberg, Miriam Poser, Peter Ebeling, Siegfried Seeber

Leuk Lymphoma· August 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Response of pseudomyxoma peritonei to gemcitabine.
Lewin Eisele, Sien-Yi Sheu, Hannes Müller-Beissenhirtz, Anja Welt, Siegfried Seeber

Acta Oncol· July 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Tumor cell dissemination in colon cancer does not predict extrahepatic recurrence in patients undergoing surgery for hepatic metastases.
Katja Schoppmeyer, Nils Frühauf, Karl Oldhafer, Siegfried Seeber, Sabine Kasimir-Bauer

Oncol Rep· February 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Serum free light chain analysis and urine immunofixation electrophoresis in patients with multiple myeloma.
Mohammad R Nowrousian, Dieter Brandhorst, Christiane Sammet, Michaela Kellert, Rainer Daniels, Siegfried Seeber

Clin Cancer Res· December 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Resection of residual disease in patients with metastatic gastrointestinal stromal tumors responding to treatment with imatinib.
Sebastian Bauer, Jörg Thomas Hartmann, Maike de Wit, Hauke Lang, Florian Grabellus, Siegfried Seeber

Int J Cancer· November 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The epidermal growth factor receptor tyrosine kinase inhibitor gefitinib sensitizes colon cancer cells to irinotecan.
Ada Henrike Braun, Katrin Stark, Olaf Dirsch, Ralf Axel Hilger, Siegfried Seeber

Anticancer Drugs· November 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Thalidomide in combination with dexamethasone for pretreated patients with multiple myeloma: serum level of soluble interleukin-2 receptor as a predictive factor for response rate and for survival.
Philipp Schütt, Peter Ebeling, Ulrike Buttkereit, Dieter Brandhorst, Bertram Opalka, Siegfried Seeber

Ann Hematol· September 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Results of a phase I trial of sorafenib (BAY 43-9006) in combination with oxaliplatin in patients with refractory solid tumors, including colorectal cancer.
Petra Kupsch, Bernhard F Henning, Katrin Passarge, Heike Richly, Katrin Wiesemann, Siegfried Seeber

Clin Colorectal Cancer· September 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase III trials in oncology: setting standards of care?
Siegfried Seeber, Ada H Braun

Nat Clin Pract Oncol· September 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficient killing of CD22+ tumor cells by a humanized diabody-RNase fusion protein.
Jürgen Krauss, Michaela A E Arndt, Bang K Vu, Dianne L Newton, Siegfried Seeber

Biochem Biophys Res Commun· June 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
In vitro dendritic cell generation and lymphocyte subsets in myeloma patients: influence of thalidomide and high-dose chemotherapy treatment.
Philipp Schütt, Ulrike Buttkereit, Dieter Brandhorst, Monika Lindemann, Sven Schmiedl, Siegfried Seeber

Cancer Immunol Immunother· May 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Chemoradiation with and without surgery in patients with locally advanced squamous cell carcinoma of the esophagus.
Michael Stahl, Martin Stuschke, Nils Lehmann, Hans-Joachim Meyer, Martin K Walz, Siegfried Seeber

J Clin Oncol· April 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase I clinical and pharmacokinetic study of the Novel Raf kinase and vascular endothelial growth factor receptor inhibitor BAY 43-9006 in patients with advanced refractory solid tumors.
Dirk Strumberg, Heike Richly, Ralf A Hilger, Norbert Schleucher, Sonke Korfee, Siegfried Seeber

J Clin Oncol· February 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The Raf kinase inhibitor BAY 43-9006 reduces cellular uptake of platinum compounds and cytotoxicity in human colorectal carcinoma cell lines.
Martina Heim, Mariam Scharifi, Jochen Zisowsky, Ulrich Jaehde, Dimitris Voliotis, Siegfried Seeber

Anticancer Drugs· February 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Raf kinase inhibitors in oncology.
Dirk Strumberg, Siegfried Seeber

Onkologie· February 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A mutation in Escherichia coli DNA gyrase conferring quinolone resistance results in sensitivity to drugs targeting eukaryotic topoisomerase II.
Thomas Gruger, John L Nitiss, Anthony Maxwell, E Lynn Zechiedrich, Peter Heisig, Siegfried Seeber

Antimicrob Agents Chemother· December 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis